Table 2. Evaluation of CD14⁺ cell and cell subsets in spleen derived MNCs of patients with primary myelofibrosis (PMF) and of healthy subjects (CTRLs).

Data are shown as median (range).

		PMF	CTRLs
	Evaluated as	(n = 16)	(n = 6)	p vs CTRLs
CD14+	% MNCs	7.3(0.7–25)	7.0(2.0–19)	0.6
Tie2+	% MNCs	6.0(1.6–41.3)	2.3(0.4–24)	0.13
Tie2+	%CD14+	27(6.0–70)	6.4(1.8–16)	0.027
Tie2+	% CD14lowCD16bright	8.0(2.3–50)	3.0(0.2–5.4)	0.028
Tie2+	% CD14lowCD16brightCD62L−CCR2−(TEMs)	9.2(0.8–47.5)	1.6(0–6.8)	0.008